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Elevated Serum Aminotransferase Level as a Predictor of
Intracerebral Hemorrhage
Korea Medical Insurance Corporation Study
Hyeon Chang Kim, MD, PhD; Dae Ryong Kang, PhD; Chung Mo Nam, PhD; Nam Wook Hur, PhD;
Jee Seon Shim, MPH; Sun Ha Jee, PhD; Il Suh, MD, PhD
Background and Purpose—Serum aminotransferase levels are known to be associated with cardiovascular risk factors, but
the relation with stroke incidence is not well known. We investigated the relation between serum aminotransferase levels
and the incidence of stroke.
Methods—We measured serum aspartate and alanine aminotransferase levels and traditional cardiovascular risk factors in
108 464 Korean men, aged 35 to 59 years, in 1990 and 1992. Serum aminotransferase levels were classified into 3
categories (35, 35 to 69, and 70 IU/L). The outcomes were hospital admissions and deaths from stroke subtypes
(ischemic stroke, intracerebral hemorrhage [ICH], and subarachnoid hemorrhage [SAH]) from 1993 to 2002.
Results—During the 10 years, 1728 ischemic, 1051 hemorrhagic (718 ICH and 222 SAH), and 243 unspecified stroke
events occurred. After adjustment for age and other traditional risk factors and according to Cox proportional-hazards
models, serum aminotransferase level had an independent positive associations with ICH. However, ischemic stroke and
SAH were not associated with aminotransferase levels. Compared with the level 35 IU/L, the adjusted relative risks
(95% confidence interval) of ICH for an aspartate aminotransferase level of 35 to 69 and 70 IU/L were 1.49 (1.21 to
1.83) and 4.21 (3.06 to 5.77), respectively. The corresponding risks for alanine aminotransferase were 1.34 (1.09 to 1.65)
and 2.89 (2.09 to 4.01), respectively. These associations were consistent regardless of the level of obesity, blood
pressure, fasting glucose, alcohol intake, and follow-up length.
Conclusions—These findings suggest that an elevated aminotransferase level is a predictor of ICH. The biologic
significance of aminotransferase level for the development of ICH merits further study. (Stroke. 2005;36:1642-1647.)
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Serum aspartate aminotransferase (AST) and alanineaminotransferase (ALT) assays are common laboratory
tests that are used for the screening of liver diseases.
Epidemiologic studies have reported positive associations
between serum aminotransferase levels and various con-
ventional cardiovascular risk factors.1– 8 Nevertheless, a
direct association between serum aminotransferase levels
and the risk of cardiovascular disease has not been fully
studied. Some patient studies reported a positive associa-
tion between hemorrhagic stroke and a history of liver
dysfunction, which was defined by elevated liver en-
zymes.9 –11 However, there are no data on the association
between aminotransferase levels and the incidence of
stroke. Therefore, we prospectively investigated the rela-
tion between serum aminotransferase levels and the 10-
year incidence of stroke by subtypes.
Methods
Study Population
The Korea Medical Insurance Corporation (KMIC) provides health
insurance to government employees, private school employees, and
their dependents. All insured workers are required to participate in
biennial health examinations, which are conducted by the KMIC. In
1990 and 1992, 95% and 94%, respectively, of workers completed
the examinations. The KMIC Study cohort therefore consisted of
115 200 male (25% random sample) and 67 932 female (100%
sample) workers, aged 35 to 59 years, who underwent the health
examinations in 1990 and 1992. We restricted these analyses to men
because the frequencies of abnormal aminotransferase levels (3.5%)
and the incidence of stroke (1.1% in 10 years) were very low for
women. We had data on major cardiovascular risk factors and serum
aminotransferase assays for 108 637 men. We excluded 173 men
who died before 1993 and enrolled 108 464 men for the analyses.
Because of missing data on smoking and/or alcohol consumption for
4170 men, 104 294 men were enrolled for the multivariate analysis.
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Institutional review board approval of the Severance Hospital at
Yonsei University was obtained for the study design.
Data Collection
Baseline information was obtained from the health examinations in
1990 and 1992, and averages of the 2 measurements were used. The
examinations were conducted in a standardized manner by trained
medical staff at 416 hospitals nationwide. The participants’ weight,
height, and blood pressure were measured at each examination.
Systolic and diastolic blood pressure was measured in the seated
position with a mercury sphygmomanometer or automatic manom-
eter. Fasting serum specimens were analyzed for total cholesterol,
glucose, and aminotransferase levels.
Data on smoking and alcohol consumption were available for
1992 only. The participants were asked to describe their smoking
status, duration, and amount. The participants were asked whether
they consumed alcoholic beverage or not, how frequently (times per
week on average) they consumed alcoholic beverage, and how much
alcohol they consumed at once. The amount of alcohol was ex-
pressed as the number of bottles of “soju,” which was the most
popular alcoholic beverage in Korea. One bottle of soju contains
72 g of ethanol. For drinkers, daily alcohol intake was calculated
from the frequency and the amount of alcohol consumption. The
participants were also asked whether they had any previously known
disease, but detailed information on diagnosis was not available.
The outcome variable was the incidence of stroke and its subtypes
(ischemic stroke, hemorrhagic stroke, intracerebral hemorrhage
[ICH] and subarachnoid hemorrhage [SAH]). The follow-up period
was the 10 years from 1993 to 2002. For individuals who had 1
stroke, we used only the first event in our analyses. We ascertained
nonfatal outcomes from health insurance claim data and fatal
outcomes from death certification data.
Statistical Analysis
Body mass index was classified into quartiles. Blood pressure level
was classified into 6 categories: optimal (systolic/diastolic 120/
80 mm Hg), normal (120 to 129/80 to 84 mm Hg), high-normal (130
to 139/85 to 89 mm Hg), and hypertension stages 1 (140 to 159/90
to 99 mm Hg), 2 (160 to 179/100 to 109 mm Hg), and 3 (180/
110 mm Hg).12 When systolic and diastolic blood pressures fell into
different categories, the higher category was selected. The categories
for fasting glucose level were 6.1, 6.1 to 6.9, and 7.0 mmol/L.
The categories for serum cholesterol level were5.2, 5.2 to 6.1, and
6.2 mmol/L. AST and ALT levels were classified into 3 categories:
35, 35 to 69, and 70 IU/L. AST and ALT levels were also
analyzed as continuous variables. Smoking was classified into 3
categories: current smokers, ex-smokers, and nonsmokers. Based on
the average daily alcohol intake, participants were classified into
nondrinkers, moderate drinkers (50g/d), and heavy drinkers
(50g/d). Cox’s proportional-hazards models were used to estimate
the relative risks of stroke subtypes according to the serum amino-
transferase level, after adjustments for age and the aforementioned
variables.
Results
At baseline, 19 291 men (17.8%) had elevated aminotrans-
ferase levels, which were defined as an AST or ALT 35
IU/L (Table 1).13 An elevated aminotransferase level was
positively associated with body mass index, blood pressure,
fasting glucose, total cholesterol, smoking, and alcohol con-
sumption (P0.001).
During the 10 years of follow-up, 3022 stroke (1728
ischemic, 1051 hemorrhagic, and 243 unspecified) events
were found to have occurred (Table 2). Of the 3022 strokes,
534 cases (17.7%) were fatal events.
Body mass index, blood pressure, fasting glucose, total
cholesterol, aminotransferase level, current smoking, and
heavy drinking were associated with the age-adjusted stroke
incidence. Blood pressure had positive associations with all
stroke subtypes, but some risk factors showed different
associations according to stroke subtypes. Body mass index
TABLE 1. Baseline Characteristics by Serum Aminotransferase Level in
108 464 Men
Baseline Characteristics
All Participants
(n108 464)
Normal
Aminotransferase*
(n89 173)
Elevated
Aminotransferase
(n19 291)
Age, y 45.0 (6.7) 45.0 (6.7) 45.6 (6.7)
Body mass index, kg/m2 23.5 (2.4) 23.3 (2.3) 24.3 (2.6)
Systolic blood pressure, mm Hg 125.5 (14.3) 124.8 (14.0) 128.5 (14.8)
Diastolic blood pressure, mm Hg 82.1 (9.6) 81.7 (9.5) 84.1 (9.9)
Fasting blood glucose, mmol/L 5.2 (1.2) 5.1 (1.2) 5.4 (1.4)
Total cholesterol, mmol/L 5.0 (0.9) 5.0 (0.8) 5.1 (1.0)
AST, IU/L 26.0 (14.6) 22.3 (5.1) 43.5 (26.6)
ALT, IU/L 25.7 (17.9) 20.7 (5.8) 49.1 (31.2)
No. (%)
Cigarette smoking
Nonsmoker 22 119 (21.2) 18 479 (21.5) 3640 (19.7)
Ex-smoker 22 207 (21.3) 18 312 (21.4) 3895 (21.0)
Current smoker 59 968 (57.5) 48 981 (57.1) 10 987 (59.3)
Average alcohol consumption
Nondrinker 26 103 (24.8) 21 881 (25.3) 4222 (22.6)
50 g/d 69 292 (65.8) 57 314 (66.2) 11 978 (64.1)
50 g/d 9900 (9.4) 7398 (8.5) 2502 (13.4)
Values are mean and (SD). Abbreviations are as defined in text.
*AST 35 IU/L and ALT 35 IU/L.
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was positively associated with ischemic stroke but negatively
associated with SAH. Total cholesterol level was signifi-
cantly associated with ischemic stroke only. Alcohol con-
sumption was significantly associated with ICH only. Ami-
notransferase level was positively associated with all strokes
and ICH, but not with ischemic stroke or SAH (data not
shown).
Even after adjustment for age and other traditional risk
factors, the serum aminotransferase level was independently
associated with the incidence of stroke. For the different
subtypes of stroke, serum aminotransferase level was strongly
associated with ICH but not with ischemic stroke or SAH.
Also, when treated as continuous variables, both AST and
ALT levels had positive associations with the incidence of
ICH (Table 3).
To examine the possible confounding effects, we evaluated
the relation between aminotransferase level and the risk of
ICH by the level of other major risk factors. The positive
association between aminotransferase level and ICH risk
could be observed at any level of other risk factors, although
the association was somewhat stronger in men with a lower
body mass index and in heavy drinkers (Figure).
Discussion
In this prospective study of Korean men, we found an
independent positive association between serum aminotrans-
ferase level and the 10-year incidence of ICH.
Aminotransferase and Traditional Risk Factors
Liver enzymes are known to be associated with several
cardiovascular risk factors.1–8,14–16 Obesity is a frequently
reported factor associated with both liver enzymes and
cardiovascular disease.1,3,5–8 However, in our analyses, body
mass index was not an important risk factor for ICH, and the
association between aminotransferase level and ICH was also
observed in men with a low body mass index. Aminotrans-
ferase levels are also known to be influenced by alcohol
intake,1,4,6,7 and heavy drinking can increase the risk of
ICH.17,18 If alcohol intake is a strong confounder between
aminotransferase level and ICH risk, then the aminotransfer-
ase level may be an indicator of alcohol-related liver damage
rather than an independent risk factor for ICH. In our data,
ICH risk was more closely related with aminotransferase
level than with alcohol consumption; age-adjusted and mul-
tivariate-adjusted risk ratios for heavy drinking were 1.83
TABLE 2. Incidence of Stroke During 10-Year Follow-Up by Serum
Aminotransferase Level
Stroke Subtype
ICD-10
Codes
All Participants
(n108 464)
Normal
Aminotransferase*
(n89 173)
Elevated
Aminotransferase
(n19 291)
All stroke I60–67 288.1 (3022) 268.8 (2331) 379.7 (691)
Ischemic I63, 65, 66 164.7 (1728) 159.0 (1379) 191.8 (349)
Hemorrhagic I60–62 100.2 (1051) 88.2 (765) 157.2 (286)
ICH I61 68.4 (718) 58.9 (511) 113.8 (207)
SAH I60 21.2 (222) 21.0 (182) 22.0 (40)
Other hemorrhage I62 10.6 (111) 8.3 (72) 21.4 (39)
Unspecified I64, 67 23.2 (243) 21.6 (187) 30.8 (56)
ICD indicates International Classification of Diseases. Other abbreviations are as defined in text.
Unit is the incidence per 100 000 person-years (No. of events).
*AST 35 IU/L and ALT 35 IU/L.
TABLE 3. Risk Ratio (95% CI) of Stroke Subtypes by Serum Aminotransferase Level at Baseline
Aminotransferase Level
Age Adjusted (n108 464) Multivariate Adjusted* (n104 294)
Ischemic Stroke ICH SAH Ischemic Stroke ICH SAH
AST, IU/L
35 1.00 1.00 1.00 1.00 1.00 1.00
35–69 1.22 (1.05–1.42) 1.94 (1.59–2.37) 1.03 (0.66–1.60) 0.99 (0.85–1.15) 1.49 (1.21–1.83) 0.96 (0.62–1.50)
70 1.16 (0.77–1.73) 5.68 (4.20–7.70) 1.83 (0.75–4.45) 0.86 (0.56–1.32) 4.21 (3.06–5.77) 1.31 (0.48–3.54)
Continuous† 1.03 (1.01–1.06) 1.10 (1.08–1.12) 1.00 (0.92–1.10) 1.00 (0.96–1.03) 1.09 (1.07–1.11) 0.97 (0.87–1.08)
ALT, IU/L
35 1.00 1.00 1.00 1.00 1.00 1.00
35–69 1.47 (1.29–1.68) 1.64 (1.35–2.00) 0.72 (0.45–1.15) 1.09 (0.95–1.25) 1.34 (1.09–1.65) 0.68 (0.42–1.10)
70 0.69 (0.44–1.08) 3.73 (2.75–5.07) 1.84 (0.91–3.72) 0.51 (0.32–0.81) 2.89 (2.09–4.01) 1.57 (0.73–3.35)
Continuous† 1.03 (1.01–1.05) 1.07 (1.06–1.09) 1.01 (0.94–1.08) 0.99 (0.97–1.02) 1.07 (1.05–1.09) 0.99 (0.91–1.08)
Abbreviations are as defined in text.
*Adjusted for age, body mass index, blood pressure, fasting glucose, total cholesterol, smoking, and alcohol consumption.
†Per 10 IU/L elevation of aminotransferase level.
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(95% confidence interval [CI], 1.43 to 2.34) and 1.21 (95%
CI, 0.93 to 1.58), respectively. Moreover, the association
between aminotransferase level and ICH was observed even
in nondrinkers. However, alcohol consumption still should be
considered a potential confounder, because alcohol consump-
tion was measured with a simple self-administered question-
naire, and past drinking was not considered. Blood pressure
and fasting glucose level were also associated with elevated
aminotransferase levels, but they did not seriously affect the
relation between aminotransferase level and ICH in our data
(Figure).
Preexisting Disease
In observational studies, undetected preexisting disease may
cause a false relation between the independent variable and
outcome events. We asked the participants whether they had
any previously diagnosed disease or not, but we had no
detailed information on the diagnoses. We further analyzed
the association between serum aminotransferase level and
ICH only for men without known disease and observed
similar results. Compared with the 35 IU/L level, the
adjusted relative risks of ICH for an AST level of 35 to 69 and
70 IU/L were 1.45 (95% CI, 1.08 to 1.95) and 3.69 (95%
CI, 2.27 to 6.01), respectively. The corresponding relative
risks for the ALT level were 1.36 (95% CI, 1.02 to 1.82) and
2.63 (95% CI, 1.60 to 4.33), respectively. We also assessed
the possible confounding effects of unknown preexisting
disease by comparing the results from different follow-up
periods, but we observed no difference by follow-up period
(data not shown).
Possible Mechanisms
The mechanism for the development of ICH in men with
abnormal liver enzymes is not fully understood. Several
previous studies reported dose-response relations between
liver dysfunction and abnormalities of almost all major
hemostatic parameters.9–11 Abnormal hemostasis may par-
tially contribute to the adverse effects of liver dysfunction on
ICH. However, it is likely that nonhemostatic mechanisms
are also involved, because impairment of the hemostatic
system in men with abnormal liver enzymes is too modest to
cause bleeding.11
A low cholesterol level has been suggested as another
mechanism of ICH in patients with liver disorders.19–21
However, a low cholesterol level does not seem to be a major
cause of the association. In our data, men with elevated
Relation between aminotransferase level and ICH by the presence of other risk factors. Risk ratios are adjusted for age, total cholester-
ol, smoking, and other variables in the figure. Vertical lines indicate 95% CIs. Abbreviations are as defined in text.
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aminotransferase levels had relatively high cholesterol levels.
Moreover, we previously reported that low cholesterol is not
an independent risk factor for ICH in the same population.22
Aminotransferase levels are highly correlated with the
-glutamyltransferase level, which has been reported to be
associated with ischemic heart disease and stroke.14–16,23–25
Several studies proposed that -glutamyltransferase may be a
marker of oxidative stress, or perhaps it is involved in the
generation of reactive oxygen species.16,25,26 However, in our
results, the serum aminotransferase level was associated only
with ICH, but not with ischemic heart disease or ischemic
stroke. This, a specific association with ICH cannot be fully
explained by oxidative stress.
Overall, the serum aminotransferase level is likely to be a
marker of liver dysfunction rather than a causal factor of ICH.
Actually, the serum aminotransferase level is a sensitive
marker of liver damage, but it does not provide information
on the underlying causes of liver damage. Although the
causal relation between aminotransferase level and ICH risk
is still unclear, serum aminotransferase levels can be used as
a predictor of ICH. The role of serum aminotransferase levels
in the development of ICH needs to be further studied.
Age and Sex Effects
The KMIC cohort members were relatively young (35 to 59
years) at baseline; thus, we could not test for an effect
modification by age group. It was reported that blood pres-
sure was strongly and directly associated with the risk of ICH
throughout middle and old age, but the association was
weakened in the older age group.27,28 However, the effect
modifications by age in other risk factors than blood pressure
are not established yet. The association between serum
aminotransferase level and the risk of ICH needs to be further
studied in wider age groups.
In a further analysis of women, we did not observe any
significant difference of ICH incidence between those with
normal versus elevated aminotransferase values. The age-
adjusted risk ratios for elevated (35 IU/L) AST and ALT
were 0.87 (95% CI, 0.28 to 2.75) and 1.06 (95% CI, 0.39 to
2.86), respectively. The sex difference in our findings could
be explained in several ways. First, sex difference in the
absolute risk of ICH may be a possible cause. A recent
meta-analysis reported that men were at 3.73 (95% CI, 3.28 to
4.25) times higher risk for ICH than women.29 Also, in our
data, men had a 3.3 times higher incidence of ICH. However,
the underlying mechanism of the sex difference is not yet
established. Second, underlying causes of aminotransferase
elevation may differ by sex. For example, if alcohol intake is
a main cause of aminotransferase elevation in men but not in
women, the relation between aminotransferase and ICH risk
can be different by sex. Thus, there is a need to examine the
underlying causes of aminotransferase elevations and their
effects on the risk of ICH. Third, the negative finding in our
further analysis of women might be due to low statistical
power. We observed only 5 cases of ICH in women with
elevated aminotransferase levels; thus, the estimated risk
ratios had wide CIs. The relation between aminotransferase
level and ICH risk in women needs to be further investigated.
Strengths and Limitations
Our study has several important strengths. First, our study
had a large sample size (108 464 men) and a long follow-up
period (10 years). Some previous studies have reported a high
frequency of liver dysfunction for patients with ICH.9–11
However, those studies had relatively small sample sizes and
case-control designs, and they failed to investigate the tem-
poral relation and possible confounding effects. Second, our
study cohort was recruited from a nationwide general popu-
lation, whereas previous studies were performed with se-
lected patient data.9–11 Third, we repeatedly measured major
independent variables over 2 years; thus, we could decrease
the possibility of measurement errors.
The study has potential limitations. First, we had no
objective information on medical history. Thus, we per-
formed further analysis for men who reported that they had
not had any previously diagnosed disease, and we discovered
similar trends. We also assessed the effects of preexisting
disease by comparing the results according to follow-up
period, and we found no significant difference. Second, the
serum aminotransferase assay was not standardized. All
hospitals, however, followed internal and external quality
control procedures, as stipulated by the Korean Society of
Quality Control in Clinical Pathology. The indexes of varia-
tion for the scores were acceptable: 107 for AST and 109 for
ALT. The misclassification bias, if any, was likely to be a
nondifferential reduction of relative risks. Third, we mea-
sured smoking status and alcohol consumption with a single
self-reported questionnaire. Alcohol consumption was asso-
ciated with both aminotransferase elevation and the risk of
ICH, and the measurement error in alcohol consumption
might be a cause of residual confounding. Finally, we could
not verify the diagnosis from hospitalization and death
certificate data. In Korea, computed tomography and mag-
netic resonance imaging are routinely used in the diagnosis of
stroke, and a radiologists’ reading is required for insurance
claims. According to a nationwide survey of 152 representa-
tive hospitals, computed tomography and/or magnetic reso-
nance imaging were used for 89% of hospital admissions for
stroke in 2000.30
Conclusions
Our findings suggest that an elevated serum aminotransferase
level may be an independent predictor of ICH. Men with
elevated serum aminotransferase levels could be regarded as
a high-risk group for ICH; they should be assessed for other
vascular risk factors and strongly recommended to control
those that are modifiable. Further studies are required on the
role of an elevated aminotransferase level in the development
of ICH.
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